| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Allison J Carroll, Delbert G Robinson, John M Kane, Avram Kordon, Jennifer Bannon, Theresa L Walunas, C Hendricks Brow. Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early-phase schizophrenia. Frontiers in health services. vol 4. 2024-10-29. PMID:39469435. |
the purpose of this study was to conduct a pre-implementation evaluation of contextual determinants of early intervention programs to implement innovations optimizing lai antipsychotic and clozapine use within a shared decision-making model. |
2024-10-29 |
2024-10-31 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain research bulletin. 2024-10-18. PMID:39424000. |
the time decision-making to start clozapine could be significantly decreased if some biomarkers were developed to assist physicians in anticipating whether a particular patient will respond to the medication. |
2024-10-18 |
2024-10-21 |
Not clear |
| Rajkumar A P, Chitra C, Bhuvaneshwari S, Poonkuzhali B, Kuruvilla A, Jacob K . Clinical Predictors of Response to Clozapine in Patients with Treatment Resistant Schizophrenia. Psychopharmacology bulletin. vol 44. issue 3. 2019-11-20. PMID:27738362. |
despite clozapine's superior clinical efficacy in treatment resistant schizophrenia (trs), its adverse effects, need for periodic leukocyte monitoring, cost and variable clinical outcomes make the therapeutic decision making process difficult and mandate a clinical need to predict its treatment response. |
2019-11-20 |
2023-08-13 |
Not clear |
| P R Falzer, D M Garma. Optimizing clozapine through clinical decision making. Acta psychiatrica Scandinavica. vol 126. issue 1. 2012-10-03. PMID:22509982. |
optimizing clozapine through clinical decision making. |
2012-10-03 |
2023-08-12 |
Not clear |
| Lisa A Mistler, Robert E Drak. Shared decision making in antipsychotic management. Journal of psychiatric practice. vol 14. issue 6. 2009-04-30. PMID:19057236. |
the similar efficacies of currently available antipsychotic medications (other than clozapine) make them appropriate for preference-sensitive care; therefore, prescribing these medications is amenable to shared decision-making. |
2009-04-30 |
2023-08-12 |
Not clear |
| Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. The Journal of clinical psychiatry. vol 59 Suppl 12. 1998-10-20. PMID:9766613. |
to evaluate the published literature about the available atypical antipsychotics--clozapine, risperidone, olanzapine, and quetiapine--and select the most appropriate treatment for specific patients, physicians need to understand the outcome measures used in clinical studies, the pharmacologic differences that explain varying side effect profiles, and pharmacoeconomic assessments that are used in the decision-making process. |
1998-10-20 |
2023-08-12 |
Not clear |